Senate · Roll call 103 · April 23, 2026
A vote to amend the 2026 budget resolution to set up a reserve fund for a government study of private or confidential drug pricing deals between federal agencies and drugmakers.
How did your own members vote? Find them by address or ZIP code
- Question
- On the Amendment
- Bill
- S.Con.Res. 33, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035.
- Details
- To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
How each party voted
Most Democrats voted Yes (44 of 45).
Most Republicans voted No (50 of 53).
Party-line vote: most Democrats and most Republicans voted on opposite sides.
About this vote
S.Con.Res. 33 is the budget resolution for fiscal year 2026. The study would be done by the Comptroller General of the United States and would examine the economic consequences of such agreements with pharmaceutical manufacturers. A deficit-neutral reserve fund allows budget levels to be adjusted later for legislation on a topic, as long as that legislation does not increase the deficit. The amendment was rejected.
This summary was drafted and checked with AI (Claude) using only the official record of the vote. Report an error
Summary by the Congressional Research Service
This concurrent resolution establishes the congressional budget for the federal government for FY2026, sets forth budgetary levels for FY2027-FY2035, and provides reconciliation instructions for legislation that increases the deficit.
How each member voted
| Member | Seat | Their vote |
|---|---|---|
| Loading… | ||